A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.

Abstract excerpt

BACKGROUND: B-Raf V600E mutations account for about half of all skin cutaneous melanoma cases, and patients with this mutation are sensitive to BRAF inhibitors. However, aberrations in other genes in the MAPK/ERK pathway may cascade a similar effect as B-Raf V600E mutations, rendering those patients sensitive to BRAF inhibitors. We rationalized that defining a signature based on B-Raf pathway activity may be more...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Line, Tumor
• Share to Melanoma
• Share to Melanoma, Cutaneous Malignant